We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
The study is carried out together with the Italfarmaco group and is analyzing the placentas of approximately 100 women who have suffered COVID-19 during their pregnancy.
Vall d'Hebron University Hospital together with the Italfarmaco group and the Anatomopathological Center of Madrid, carry out a research project to study the placental tissue of a hundred women infected by the SARS-CoV-2 virus during pregnancy.
Current evidence indicates that among the manifestations associated with the SARS-CoV-2 virus are thrombotic complications. These manifestations occur as a consequence of a hypercoagulable state that is usually related to the severity of the infection, which could be added to the risk inherent in pregnancy itself.
Therefore, pregnant women are being an important focus of attention, monitoring and research in the current pandemic caused by COVID-19.
The placenta is a highly vascularized organ, which provides oxygen and nutrients to the developing baby. Certain alterations in the placenta have been linked to problems in pregnancy and in the health of the newborn.
In this sense, Plaxavid study coordinated by Dr. Anna Suy, head of the Obstetrics Section of the Vall d'Hebron University Hospital and in which the Pathological Anatomy Service at the Vall d'Hebron Hospital, the Italfarmaco group and the Anatomopathological Center of Madrid participate, is analyzing the placentas of approximately 100 women who have suffered COVID-19 during their pregnancy. "The main objective of this study is to evaluate the existence of signs of poor vascular perfusion that may translate into a predisposition or a greater occurrence of thrombosis in the placental tissue",explains Dr. Anna Suy, principal investigator of the study and the research group of Fetal Maternal Medicine at the Vall d'Hebron Research Institute (VHIR). "Other placental alterations and their relationship with the clinical characteristics of pregnant women, with the appearance of certain problems of pregnancy, or of the newborn will also be analyzed", she adds.
Specifically, the Plaxavid Study will provide data on the prothrombotic state that has been related to the COVID-19 pathology and its possible placental impact, while contributing to the knowledge of the effects of this infection on pregnancy.
“The results of this study will contribute to improving the efficient management of pregnant women who have suffered from COVID-19 infection and of her newborn”, concludes Dr. Suy.
Dr. José Montans, director of the Anatomopathological Center of Madrid, responsible for carrying out the histopathological study of the placentas, tells us about the value of this study: “It is a unique approach to date to a problem that has not been sufficiently evaluated: to study the impact of the disease on pregnant women with COVID-19 from a clinical, analytical, pathological and to some extent epidemiological point of view. From the anatomopathological point of view, it will allow to systematically evaluate all possible vascular and inflammatory lesions in the placenta and their correlation with clinical data, both from the point of view of the evolution of the pregnancy and the evolution of COVID in these patients”.
Obstetrics, Children's Hospital and Woman's Hospital
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.